Published in

Elsevier, Journal of Emergency Medicine, 1(61), p. 116, 2021

DOI: 10.1016/j.jemermed.2021.06.003

American Heart Association, Stroke, 10(52), p. 3410-3413, 2021

DOI: 10.1161/strokeaha.121.035948

Massachusetts Medical Society, New England Journal of Medicine, 20(384), p. 1910-1920, 2021

DOI: 10.1056/nejmoa2030297

Links

Tools

Export citation

Search in Google Scholar

Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Basilar artery occlusion stroke is known to have poor outcome with a high rate of morbidity and mortality despite best medical therapy. Since the original report of intra-arterial therapy for basilar artery occlusion in 1983, two recent randomized trials comparing endovascular therapy versus best medical management were completed on a large scale, BASICS (Basilar Artery International Cooperation Study) and the BEST trial (Basilar Artery Occlusion Endovascular Intervention Versus Standard Medical Treatment), both of which demonstrated equivocal benefit of the two modalities. In this commentary, we comment and highlight important lessons related to basilar occlusion stroke as learned from the BASICS and BEST randomized trials.